linjc16/ctgov huggingface dataset:
Gender Discrimination Against Female Surgeons A Study in a Lower-Middle-Income Country

Study Overview
=================
Brief Summary
-----------------
our study explores how GD is perceived and reported by surgeons in Pakistan.

Detailed Description
-----------------
Due to an increasing spotlight, gender discrimination (GD) is identified and reported in many aspects of surgical training and practice in the developed world 1, 2. In contrast, lower-middle-income countries like Pakistan lack awareness and strategies to counteract GD, which manifests as a lack of females in leadership and academic positions, and pay inequities. GD often occurs insidiously, as a result of complex interplay between societal norms, gender stereotypes and learned behaviors. Thus, our study identifies how GD is perceived and reported by surgeons in Pakistan.

Official Title
-----------------
Gender Discrimination Against Female Surgeons May Pass Unrecognized: A Study in a Lower-Middle-Income Country

Conditions
-----------------
Gender Issues

Intervention / Treatment
-----------------
* Other: no intervention carried out


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all consultants fellows instructors medical officers residents working in the Department of Surgery Exclusion Criteria: all consultants fellows instructors medical officers residents not working in the Department of Surgery

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention carried out|no intervention was done|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gender bias | Gender bias faced by female surgeons | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| experience of gender discrimination | as in by whom were they gender discriminated | 2 months |
Atorvastatin in Moderate Active Crohns Disease

Study Overview
=================
Brief Summary
-----------------
Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.

Conditions
-----------------
Crohns Disease

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Crohns disease C-reactive protein level > 2 mg/L in absence of an infection Fecal calprotectin > 250 mg/kg or CDAI > 150 Exclusion Criteria: CDAI > 450 Prednisolone dosage above 15 mg/day

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atorvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory markers in plasma before and after treatment. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in clinical activity index and mucosal inflammation after treatment. |  |  |
Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database

Study Overview
=================
Brief Summary
-----------------
The doctor's overridden rate for Drug-drug interaction (DDI) alert systems was 85-95% in foreign and there was more than 90% overridden rate in Taiwan. Why DDI alerts systems which spent much time and money to establish could not use medicinal information to increase drug safety? One of the reasons which induced to override was that health care thought there were too much DDI alerts and high false alerts. The difference between DDI alert systems from pharmacists to confirm drug-drug interaction was that pharmacists not only confirmed ordering drug at the same time but also checked the other drug information such as frequency, rote and refill etc. Therefore, DDI alert systems which were established by drug code alone would induce a lot of false alerts. In order to study how much false alert rate in drug-drug interactions, this research selected most common drug-drug interaction which was antacids and antibiotics. Antacids were most self-payment so this research needed to analyze ROCDR (Establishing a Multi-Center, Longitudinal, Research-Oriented Clinical Data Repository for Clinical Research). The aim was to study how many drug-drug interactions and false alerts from antacids and antibiotics and analyze the difference in different department. Finally, proposing advice and assessment for building drug-drug interaction alerts system to strength drug information system and increase drug safety.

Official Title
-----------------
Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database

Conditions
-----------------
Drug Interaction Alert

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Select DDI rules: antacids and antibiotics Database: ROCDR (multicenter clinical database) The pharmacists defined six rules which were based on medical knowledge for true alerts or false-alert. True alert: Rule 1 and Rule 2 False-alert: Rule 3 or Rule 4 Other (Unable to determine): Rule 5 or Rule 6 Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ROCDR
Effect of Anesthesia Method on Neutrophil-Lymphocyte Ratio

Study Overview
=================
Brief Summary
-----------------
The neutrophil/lymphocyte ratio (NLR) is a simple and inexpensive marker of the inflammatory response. NLR is affected not only by surgical trauma but also by the anesthetic method. The method of anesthesia can affect NLR, thereby modulating the inflammatory response and surgical outcomes. In this study, it was aimed to evaluate the relationship between blood NLR and anesthesia techniques in patients undergoing forearm surgery, and the secondary aim was to evaluate the relationship between Platelet/lymphocyte ratio (TLR), Mean Platelet Volume (MPV) and anesthesia techniques.

Official Title
-----------------
The Effect of Anesthesia Method on Neutrophil-Lymphocyte Ratio in Patients Undergoing Forearm Surgery

Conditions
-----------------
Inflammation, Anesthesia

Intervention / Treatment
-----------------
* Procedure: peripheral nerve block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Underwent forearm surgery Between aged 18-70 Under general anesthesia or peripheral nerve block Exclusion Criteria: acute infection morbid obesity chronic treatment with steroids or immunosuppressants recently received chemotherapy hepatic and renal dysfunction; chronic alcohol abusers Multiple trauma Patients with missing data in their files

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group G<br>Patients Undergoing Forearm Surgery under general anesthesia | |
| Group P<br>Patients Undergoing Forearm Surgery under peripheral nerve block | Procedure: peripheral nerve block<br>* local anesthetic application to the brachial plexus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neutrophil/lymphocyte ratio | Differences in neutrophil-lymphocyte ratio between patients who underwent general anesthesia and peripheral nerve block | up to 24 hours after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet/lymphocyte ratio | Differences in Platelet/lymphocyte ratio between patients who underwent general anesthesia and peripheral nerve block | up to 24 hours after surgery | 
| Mean Platelet Volume | Differences in Mean Platelet Volume between patients who underwent general anesthesia and peripheral nerve block | up to 24 hours after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
General Anesthesia, Neutrophil Lymphocyte Ratio, Peripheral Nerve Block
ImPACT Version 4-Touchscreen: Normative and Reliability Study

Study Overview
=================
Brief Summary
-----------------
This research study is designed to establish normative database and reliability of ImPACT for adolescents and adults ages 12 through 80 to expand the use of devices to include touchscreen.

Detailed Description
-----------------
This research study is designed to establish normative database and reliability of ImPACT for adolescents and adults ages 12 through 80 to expand the use of devices to include touchscreen. Enrollment will be 900 participants.

Official Title
-----------------
ImPACT Version 4-Touchscreen: Normative and Reliability Study

Conditions
-----------------
Concussion

Intervention / Treatment
-----------------
* Device: Normative
* Device: Reliability


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 12-80 Primary English speaking or fluent in English Exclusion Criteria: Documentation of a known special education diagnosis other than a 504 designation. History of concussion less than 6 months to the study participation Known physical (e.g., visual impairment not fixable by usual means, such as glasses) or psychological impairment (ADHD, LDD, etc.) that would affect their ability to perform the test.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Normative<br>ImPACT will be administered to participant's for a baseline test. | Device: Normative<br>* ImPACT will be administered at baseline testing<br>|
| Other: Reliability<br>ImPACT will be administered to participant's within 60 days of baseline test. | Device: Reliability<br>* ImPACT will be administered again within 60 days of baseline test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validity | ImPACT Touchscreen performs within normal parameters of ImPACT Online | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reliability | Reliability will be established through a test/re-test. ImPACT Touchscreen will be administered at 2 time points to establish results should be stable over time. | Baseline test will be administered at enrollment and re-test will be administered within 60 days of baseline test. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain
Contralateral ReSTOR / Monofocal or Phakic Eye

Study Overview
=================
Brief Summary
-----------------
Bilateral evaluation of unilateral implantation of ReSTOR and contralateral monofocal or phakic eye.

Official Title
-----------------
Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye

Conditions
-----------------
Cataracts

Intervention / Treatment
-----------------
* Device: ReSTOR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unilateral operable cataract Candidate for presbyopic intraocular lens (IOL) Exclusion Criteria: Ocular comorbidities compromising primary outcome Bilateral cataracts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Monofocal<br>Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye | Device: ReSTOR<br>* AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted<br>|
| Active Comparator: Phakic<br>Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending | Device: ReSTOR<br>* AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity | Uncorrected Visual Acuity (VA) is measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution. A lower logMAR value indicates better visual acuity. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast Sensitivity | Contrast sensitivity is the measurement of one's ability to detect slight changes in luminance before it becomes indistinguishable. It is measured in logarithmic (log) units by means of an illuminated box, the CSV 1000 by Vector Vision. A higher value for the logarithmic units translates to better contrast sensitivity. | 6 Months | 
| Patient Satisfaction | Average rating of patient satisfaction based on a patient survey. The survey had a 10 point scale (10 being most satisfied and 0 being most unsatisfied). | 6 Months Postoperative | 
| Spectacle Independence | The percentage of patients reporting spectacle independence (no longer needing to wear glasses). | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AcrySof, ReSTOR, Multifocal, Intraocular Lens
Fatigue in Dystonia (a Single Session, Questionnaire-based Study of Fatigue in Dystonia)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine how common fatigue and sleepiness are in patients with dystonia.

Detailed Description
-----------------
The purpose of the study is to determine the prevalence of fatigue in patients with dystonia. There are many factors which may impact fatigue but perhaps the most important of these is sleep. It is therefore critical that we collect data on sleep habits and sleepiness to help interpret our data on fatigue. We will be using the Epworth Sleepiness Scale to assess daytime somnolence and the Parkinson's Disease Sleep Scale to assess the presence or absence of common sleep disorders affecting patients with movement disorders along with the Multidimensional Fatigue Inventory and the Fatigue Severity Scale.

Official Title
-----------------
Fatigue in Dystonia (IRB No. 108-2008)

Conditions
-----------------
Dystonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of dystonia Informed consent to be contacted about research Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with dystonia<br>Patients with dystonia, 21-100 years of age. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the prevalence of fatigue and sleepiness in patients with dystonia. |  | At the time of their visit. |
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety of soluble beta-glucan (SBG) in combination with antibody and chemotherapy treatment in patients with non-Hodgkin-s lymphoma.

Official Title
-----------------
A Phase I Study to Determine the Safety and Effect of Soluble Beta-Glucan (SBG) in Combination With Rituximab and COP/CHOP in Patients With Non'Hodgkin's Lymphoma

Conditions
-----------------
Non-Hodgkin's Lymphoma

Intervention / Treatment
-----------------
* Drug: Soluble beta-glucan (SBG)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CD20 positive B-cell non-Hodgkin's lymphoma Treatment with rituximab and CHOP or COP Performance status 0 or 1 according to the WHO scale (Appendix) Expected lifetime of more than 12 weeks Age ≥ 18 years The patient must be able and willing to comply with the study procedures, and signed and dated informed consent must be obtained Exclusion Criteria: Women who are pregnant or breast-feeding. For fertile women, a negative pregnancy test must be provided during the screening test. Women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation Lymphoma involvement of central nervous system Reduced bone marrow function defined by leukocyte counts < 3.0 x 109/l, neutrophil counts < 1.5 x 109/l, thrombocyte counts < 100 x 109/l or hemoglobin < 10 g/dl Reduced liver function defined by bilirubin > 1.5 x upper limit of normal (ULN) or ASAT/ALAT ≥ 3 x ULN Reduced renal function defined by serum creatinine ≥ 2 x ULN

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Soluble beta-glucan (SBG)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Heparin Binding Protein as a Prognostic Biomarker of Sepsis Severity

Study Overview
=================
Brief Summary
-----------------
the aim of the study is to correlate between the severity of sepsis and serum heparin binding protein in the patients admitted to ICU with sepsis., and detect its value as a prognostic biomarker in sepsis

Official Title
-----------------
Heparin Binding Protein as a Reliable Prognostic Biomarker for Severity of Sepsis in the Intensive Care Unit

Conditions
-----------------
Sepsis, HBP

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult whose age between 20 to70 years old patients suffered from sepsis or septic shock (under the third international consensus definition of sepsis and septic shock) Exclusion Criteria: Any pregnancy female Any patient who is Neutropenic secondary to malignancy Patients who is taking immunosuppressive therapy Patients who is suffering fromHematological malignancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the level of Heparin binding protein in relation to patient clinical improvement measured by SOFA Score | Correlates the change of the level of Heparin binding protein in ng/ml to the clinical improvement of the patients which is measured by SOFA score | 72 hours after meeting sepsis ceriteria | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heparin binding protein and mortality | Correlates the change of the level of Heparin binding protein in ng/ml And how can it is used to predict mortality | 28 days after meeting sepsis ceriteria |
Evaluation of Image Quality Over Time After Injection of the ﬂuorescein Sodium for Confocal Laser Endomicroscopy

Study Overview
=================
Brief Summary
-----------------
Confocal laser endomicroscopy (CLE) is a newly developed endoscopic technique. The most commonly used fluorescent substance is Fluorescein sodium.The plasma half-life of ﬂuorescein is 11 minutes. A recent test estimated that ﬂuorescein-based CLSM(confocal laser scanning microscopy) of the upper-GI tract of pigs delivers the best contrast and image quality within the ﬁrst 8 minutes after injection of ﬂuorescein .However, despite its increasing use in clinical examination,there are no data on contrast dynamics and image quality over time after injection of the ﬂuorescein sodium in the inspection of gastrointestinal tract of human being.

Official Title
-----------------
Evaluation of Image Quality Over Time After Injection of the ﬂuorescein Sodium for Confocal Laser Endomicroscopy

Conditions
-----------------
Change of Image Quality of CLE

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: These subjects will include male or female aged between 18 and 60 years with indications for upper-endoscopy ,but without serious gastritis and other serious stomach lesions Exclusion Criteria: Complications such as gastric and/or duodenal peptic ulcer, stenosis Esophageal, gastric or duodenal cancer or other malignancy History of stomach surgery A history of bronchial asthma, or known allergy to fluorescein. Pregnant or breast-feeding (for females) Below 18 or above 60 years of age Severe comorbidities ( e.g. such as renal failure, congestive cardiac failure, liver cirrhosis).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The ideal time period for the best CLE imaging when using ﬂuorescein sodium is about 10 minutes |  | Within the 30 minutes after injection of fluorescein |